BeyondSpringBYSI
About: BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
Employees: 36
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
2,788% more call options, than puts
Call options by funds: $231K | Put options by funds: $8K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0.8% less ownership
Funds ownership: 15.13% [Q1] → 14.33% (-0.8%) [Q2]
18% less funds holding
Funds holding: 22 [Q1] → 18 (-4) [Q2]
34% less capital invested
Capital invested by funds: $21.1M [Q1] → $13.9M (-$7.21M) [Q2]
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Research analyst outlook
We haven’t received any recent analyst ratings for BYSI.